...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of Clinical and Diagnostic Research >Recent Advances In Antiretroviral Therapy
【24h】

Recent Advances In Antiretroviral Therapy

机译：抗逆转录病毒疗法的最新进展

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Despite significant progress in the study of human immunodeficiency virus (HIV) infection over the past few years, it still remains a leading cause of death throughout the world. The field of antiretrovirals is dramatically growing. 25 antiretroviral drugs have been approved by the US-FDA till date. The development of newer antiretrovirals has dramatically altered the progression of the disease and has improved the quality of life in many HIV-infected patients. Over the last two years, three novel antiretroviral drugs, maraviroc (CCR5 antagonist), raltegravir (integrase inhibitor) and etravirine (a second generation non nucleoside reverse transcriptase inhibitor) have been approved by the FDA and several others are in the pipeline. This review discusses the pharmacology of the three novel antiretroviral agents. Drugs which are currently in the pipeline and the latest HIV treatment guidelines have also been addressed.
机译：尽管在过去的几年中，人类免疫缺陷病毒（HIV）感染的研究取得了重大进展，但它仍然是全世界死亡的主要原因。抗逆转录病毒药物的领域正在急剧增长。迄今为止，已经有25种抗逆转录病毒药物被US-FDA批准。新型抗逆转录病毒药物的开发极大地改变了疾病的进程，并改善了许多感染HIV的患者的生活质量。在过去的两年中，FDA批准了三种新的抗逆转录病毒药物maraviroc（CCR5拮抗剂），raltegravir（整合酶抑制剂）和etravirine（第二代非核苷逆转录酶抑制剂），还有其他几种药物正在筹备中。这篇评论讨论了三种新型抗逆转录病毒药物的药理作用。目前正在准备中的药物和最新的HIV治疗指南也已得到解决。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号